Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. - Wikidata - wikimedia - TriplyDB

Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.

Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.

http://www.wikidata.org/entity/Q39910421

about

Stem-like ovarian cancer cells can serve as tumor vascular progenitors TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Antivascular therapy for epithelial ovarian cancer.The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells.Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy.Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.Current status of maintenance therapy for advanced ovarian cancer.Immunization with synthetic VEGF peptides in ovarian cancer Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.Angiogenesis-related pathways in the pathogenesis of ovarian cancer Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer.Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment.Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer.Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.Bevacizumab: a review of its use in advanced cancer.Anti-angiogenic agents in ovarian cancer: past, present, and future.Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.Beyond antiangiogenesis: intratumorally injected bevacizumab plays a cisplatin-sensitizing role in squamous cell carcinomas in mice.Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma.Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis.Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface.Targeting the Microenvironment in High Grade Serous Ovarian Cancer

P2860

Q30491933-582A4667-E850-4ED0-911B-90057E4D437C Q33553922-F6AB9131-AE96-421F-9FF3-21D4D4A37F93 Q33583598-89260F23-251A-4A78-A11D-6C8F94DDCC70 Q33727047-65D5A22B-89B0-4358-B62F-7D5D528AFE9B Q33884456-A9C0825F-0385-48D3-A349-0AC0F96E78D1 Q34048965-B8C388D6-E582-496D-98A1-0658BF8E395D Q34139923-5DE1241F-5178-4E76-BEDA-A2C62BD43B9B Q34271924-D41E48D8-39BC-4D81-AE0E-0915B004F398 Q34901858-856CD65D-C043-4439-8EE9-E599989B7F08 Q35233993-2F0BAC01-87E1-440C-B187-07FD52EF479A Q35470322-6B3B1C3C-3BFF-4385-8798-C3CFD204F311 Q35954103-8D36B420-AFE6-4B27-9C2D-C1480F133153 Q35995186-8C96A657-6FDE-4221-8549-56A5CCDD4562 Q36089989-893C1EBD-4092-4854-B400-67F8D9951E48 Q36230572-B99D3F8A-7BED-4FC8-A52A-F9662AB90B6F Q37102447-7A13E999-F7D7-4E3B-8BFB-3E7DB4249E97 Q37139109-F28F13D9-8DA3-42CD-A3EE-A0D25D2ED6D4 Q37220528-F258715F-F180-4373-95A1-DBE295D70EA1 Q37374843-83D2AA6D-B0BE-43E2-9BBE-34D945B646AB Q37529822-EF24BBBB-C7C9-4E54-BEE3-D2EA4E5453B9 Q37731321-38AD3EF7-9583-4696-B9E2-E0CCE348085F Q37735605-70983A64-A1A5-4925-8FCA-71B7E51A21B3 Q37833570-2DE8EA40-3D56-479F-AB95-4E1CDABBC348 Q38003707-0BF1342F-E817-4631-8950-76431CA8C5D1 Q38111265-77F2C933-9630-4F09-9AB1-E7572BF72DC5 Q38222277-33DA2632-52A3-4F5D-9A50-4D2B96155A05 Q38260176-CDC7CCE0-FBFD-4131-ACFB-8AB0AC60E48A Q38872239-D36A89C0-BB47-45D8-B16B-197795BBB940 Q39324636-8A8EF9F4-F8D1-4C47-879F-C17EFF2AB632 Q39396206-644D8F88-53AB-4599-9570-1F6698665858 Q39539497-97CB85AE-4CBA-4FD8-975A-AC90848D86D1 Q41878285-719A7FA6-14FB-4C97-B3E2-C86F48D83514 Q46016818-12473340-938C-499A-B032-4AC6523230FB Q50129142-4B44AAAE-7D79-435A-9211-0D3BA5A5E3FC Q55196550-B8EF1A25-5765-4655-9060-C44BF182CA5D Q58789499-E03F700B-D358-4808-848C-A7BE0404004B

P2860

Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.

http://www.wikidata.org/entity/Q39910421

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Maintenance treatment with bev ...... in vivo ovarian cancer model.

@en

Maintenance treatment with bev ...... in vivo ovarian cancer model.

@nl

type

label

Maintenance treatment with bev ...... in vivo ovarian cancer model.

@en

Maintenance treatment with bev ...... in vivo ovarian cancer model.

@nl

prefLabel

Maintenance treatment with bev ...... in vivo ovarian cancer model.

@en

Maintenance treatment with bev ...... in vivo ovarian cancer model.

@nl

P1433

Q39910421-CE5CD09B-4B1F-4FDA-AF27-9D7E8E2BDAE4

P1476

Q39910421-3AF44F67-FCD4-41BF-BEA6-C8E5B7341910

P2093

Q39910421-02F992A0-A89D-4B4C-BFB3-B6823FD25259

Q39910421-0507E1FC-C779-49AA-B818-A3D370D5CAC3

Q39910421-0C90904F-F8E6-4B04-A7D7-15C2B7DF12E0

Q39910421-48FA5A25-47D3-4D44-95C3-838A707FA713

Q39910421-4F89B24D-49C5-409C-95C8-6E0F65140548

Q39910421-88D1E84A-F217-41F1-AB0F-D9921E06ACCC

Q39910421-9EDB41AD-0006-4EF8-A60F-3D39FB484BC5

Q39910421-A1B714BC-DDC0-40B6-B359-6B9B31E9DF18

Q39910421-B36D5810-4A8C-42FE-AC84-0A8480A415B1

Q39910421-D61B2AB1-1335-4145-8A9E-F852EE67BD58

P304

Q39910421-9CB6DC55-4824-4F23-A58B-736EF00406F5

P31

Q39910421-F2A4864A-364E-4DEA-8227-0F9171195BB2

P356

Q39910421-B6A39566-9FE7-4E7F-8849-3C5D5B7A0E3E

P407

Q39910421-B552018E-07EE-462A-A5CD-6695C207C358

P433

Q39910421-284A54B5-E5A2-4F6D-9F1C-D40834CCD078

P478

Q39910421-C064AA19-160D-4589-97BE-D73ACEFED855

P577

Q39910421-DE8A4F88-B861-407B-982A-01F6BBCBD3C8

P5875

Q39910421-637348DC-705F-41D5-AD6D-6CB16FA49C99

P698

Q39910421-E9B43914-AA0C-42EB-8F23-F905C9C1D9D7

P921

Q39910421-339F52F0-5598-417D-BD05-45ACD93EC7F2

Q39910421-E78BD37A-1884-4901-B277-3AA07B80A85A

P356

1078-0432.CCR-08-0243

P1433

Clinical Cancer Research

P1476

Maintenance treatment with bev ...... in vivo ovarian cancer model.

@en

P2093

Akiko Tanabe-Kimura

http://www.w3.org/2001/XMLSchema#string

Hiroshi Sasaki

http://www.w3.org/2001/XMLSchema#string

Kenichiro Morishige

http://www.w3.org/2001/XMLSchema#string

Masahide Ohmichi

http://www.w3.org/2001/XMLSchema#string

Masahiro Sakata

http://www.w3.org/2001/XMLSchema#string

Masanori Kanemura

http://www.w3.org/2001/XMLSchema#string

Robert A Burger

http://www.w3.org/2001/XMLSchema#string

Satoshi Tsunetoh

http://www.w3.org/2001/XMLSchema#string

Seiji Mabuchi

http://www.w3.org/2001/XMLSchema#string

Tadashi Kimura

http://www.w3.org/2001/XMLSchema#string

P304

7781-7789

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-0243

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23560038

http://www.w3.org/2001/XMLSchema#string

P698

19047105

http://www.w3.org/2001/XMLSchema#string

P921